Cefepime distribution by microdialysis in peritoneal fluid of rats with or without experimental peritonitis.
Cefepime
intraperitoneal infection
microdialysis
pharmacokinetics
Journal
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ISSN: 1600-0463
Titre abrégé: APMIS
Pays: Denmark
ID NLM: 8803400
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
received:
11
12
2023
accepted:
09
04
2024
medline:
25
4
2024
pubmed:
25
4
2024
entrez:
25
4
2024
Statut:
aheadofprint
Résumé
The aim of this study was to investigate the penetration of cefepime into rat peritoneal fluid by microdialysis and to determine the relationship between unbound drug plasma and tissue concentration in healthy animals and in a sepsis model established through cecal ligation and puncture-induced peritonitis. Probe recovery was performed by dialysis and retrodialysis. Cefepime was administered at a dose of 110 mg/kg intravenously. Samples were collected for about 4 h, and concentrations were determined by liquid chromatography-electrospray ionization-QTOF MS. Tissue penetration was also determined. Probe recovery in vivo was 38.78% ± 3.31% and 38.83% ± 2.74% in the control and peritonitis groups, respectively. Cefepime was rapidly distributed in the peritoneal fluid in both groups. The peritoneal fluid/plasma cefepime ratio was 0.38 and 0.32 for the control and peritonitis groups, respectively. Cefepime concentrations were above the MIC of 4 mg/L for the main enterobacteria. The infection model that was used had no apparent effect on the pharmacokinetics of cefepime in rats. This was the first study to determine free cefepime concentrations in the peritoneal fluid of healthy rats and rats with experimental peritonitis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Scandinavian Societies for Pathology, Medical Microbiology and Immunology.
Références
Barshak MB. Official reprint from UpToDate antimicrobial approach to intra‐abdominal infections in adults [Internet]. 2023. www.uptodate.com
Chauzy A, Lamarche I, Adier C, Couet W, Marchand S. Microdialysis study of aztreonam‐avibactam distribution in peritoneal fluid and muscle of rats with or without experimental peritonitis. Antimicrob Agents Chemother. 2018;62(10):34–37.
Daskalopoulou D, Kankam J, Ambe PC, Zarras K. Single‐center retrospective analysis of the outcomes of patients undergoing staged peritoneal lavage for secondary peritonitis. World J Surg. 2020;44(7):2185–2190.
Ross JT, Matthay MA, Harris HW. Secondary peritonitis: principles of diagnosis and intervention. BMJ. 2018;361:k1407.
Pais GM, Chang J, Barreto EF, Stitt G, Downes KJ, Alshaer MH, et al. Clinical pharmacokinetics and pharmacodynamics of cefepime. Clin Pharmacokinet. 2022;61(7):929–953.
Masich AM, Heavner MS, Gonzales JP, Claeys KC. Pharmacokinetic/pharmacodynamic considerations of beta‐lactam antibiotics in adult critically ill patients. Curr Infect Dis Rep. 2018;20(5):9.
Endimiani A, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti‐Infect Ther. 2008;6:805–824.
Liu P, Müller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents. 2002;19(4):285–290.
Marchand S, Chauzy A, Dahyot‐fizelier C, Couet W. Microdialysis as a way to measure antibiotics concentration in tissues. Pharmacol Res [Internet]. 2016;111:201–207.
Deitchman AN, Heinrichs MT, Khaowroongrueng V, Jadhav SB, Derendorf H. Utility of microdialysis in infectious disease drug development and dose optimization. AAPS Journal. 2017;19(2):334–342.
Finazzi S, Luci G, Olivieri C, Langer M, Mandelli G, Corona A, et al. Tissue penetration of antimicrobials in intensive care unit patients: a systematic review—part I. Antibiotics. 2022;11(9):1164.
Lefeuvre S, Marchand S, Lamarche I, Mimoz O, Couet W, La MCHU. Microdialysis study of imipenem distribution in the intraperitoneal fluid of rats with or without experimental peritonitis. Antimicrob Agents Chemother. 2006;50(1):34–37.
Dahyot‐Fizelier C, Lefeuvre S, Laksiri L, Marchand S, Sawchuk RJ, Couet W, et al. Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. Clin Pharmacokinet. 2010;49(5):323–334.
Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther. 2008;83(3):452–459.
Mameli M, Vezzelli A, Verze’ S, Biondi S, Motta P, Greco A, et al. Liquid chromatography–tandem mass spectrometry for the simultaneous quantitation of enmetazobactam and cefepime in human plasma. J Pharm Biomed Anal. 2019;174:655–662.
Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock—A review of laboratory models and a proposal. J Surg Res. 1980;29(2):189–201.
Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW, Bland KI, et al. Cecal ligation and puncture. Shock. 2005;24(1):52–57.
Nemzek JA, Hugunin KM, Opp MR. Modeling sepsis in the laboratory: merging sound science with animal well‐being. Comp Med. 2008;58(2):120–128.
Bernardi PM, Barreto F, Dalla CT. Application of a LC–MS/MS method for evaluating lung penetration of tobramycin in rats by microdialysis. J Pharm Biomed Anal. 2017;134:340–345.
dos Anjos MV, Possa E, da Silva Fonseca G, Bergoza L, dos Santos PR, Moura e Silva S, et al. Development and validation of an LC–ESI–QTOF–MS method to measure cefepime in the plasma and peritoneal fluid of rats using microdialysis: application in a pilot pharmacokinetic study. Biomed Chromatogr. 2022;36(11):e5470. https://doi.org/10.1002/bmc.5470
Sorbello AA, Damy SB, Osaka JT, Andretto R, França LC, Zanotto A, et al. Comparative analysis of the evolution of the induced peritonitis by a standardized inoculum of Escherichia coli in rats – controls, laparotomy and pneumoperitoneum with carbon dioxide. Rev Bras de Video‐Cir. 2003;1(1):1–8.
Comar SR, Schulz T, Machado N d A, França F d S, Haas P. Análise citológica do líquido peritoneal. Estudos de Biologia Ambiente e Diversidade. 2011;33:73–80.
Hammarlund‐Udenaes M. Microdialysis as an important technique in systems pharmacology—a historical and methodological review. AAPS Journal. 2017;19(5):1294–1303.
de Lange CME, Bock G, Schinkel HA, Boer GA, Breimer DD. BBB transport and P‐glyciprotein functionality using MDR1A (−/−) and wild‐tipe mice. Total brain versus microdialysis concentration profiles of rhodamine‐123. Pharm Res. 1998;15:1657–1665.
de Lange EC, Marchand S, van den Berg DJ, van der Sandt IC, de Boer AG, Delon A, et al. In vitro and in vivo investigations on fluoroquinolones; effects of the P‐glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci. 2000;12:85–93.
Zimmermann ES, Laureano JV, Dos Santos CN, Schmidt S, Lagishetty CV, De Castro WV, et al. Simultaneous semimechanistic population analyses of levofloxacin in plasma, lung, and prostate to describe the influence of efflux transporters on drug distribution following intravenous and intratracheal administration. Antimicrob Agents Chemother. 2016;60(2):946–954.
Heinen JE, Freddo RJ, Costa TD. Penetração tecidual de antibióticos. Caderno de Farmácia. 2001;17(1):9–18.
Mimoz O, Leotard S, Jacolot A, Padoin C, Louchahi K, Petitjean O, et al. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem‐hydrolyzing β‐lactamase‐ producing strain of Enterobacter cloacae. Antimicrob Agents Chemother. 2000;44(4):885–890.
Pacifici GM, Marchini G. Clinical pharmacology of cefepime in infants and children. Int J Pediatr. 2017;5(4):4723–4740.
Breilh D, Boselli E, Bel JC, Chassard D, Saux MC, Allaouchiche B. Diffusion of cefepime into cancellous and cortical bone tissue. J Chemother. 2003;15(2):134–138.
Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, et al. Steady‐state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003;31(8):2102–2106.
Gloor B, Worni M, Strobel O, Uhl W, Tcholakov O, Müller CA, et al. Cefepime tissue penetration in experimental acute pancreatitis. Pancreas. 2003;26(2):117–121.
Ritter L, Bergoza L, Possa E, Tasso L. Is clindamycin a potential treatment for prostatitis? APMIS. 2022;130(4):197–205.
Tsai YH, Bies M, Leitner F, Kessler RE. Therapeutic studies of cefepime (BMY 28142) in murine meningitis and pharmacokinetics in neonatal rats. Antimicrob Agents Chemother. 1990;34:733–738.
Chang YL, Chou MH, Lin MF, Chen CF, Tsai TH. Determination and pharmacokinetic study of unbound cefepime in rat bile by liquid chromatography with on‐line microdialysis. J Chromatogr A. 2002;961(1):119–124.
So W, Kuti JL, Shepard A, Nugent J, Nicolau DP. Tissue penetration and exposure of cefepime in patients with diabetic foot infections. Int J Antimicrob Agents. 2016;47(3):247–248.
Avedissian SN, Pais G, Joshi MD, Rhodes NJ, Scheetz MH. A translational pharmacokinetic rat model of cerebral spinal fluid and plasma concentrations of cefepime. mSphere. 2019;4(1):1–11.
Tauber MG, Hackbarth CJ, Scott KG, Rusnak MG, Sande MA, General Hospital F, et al. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits [Internet]. Antimicrob Agents Chemother. 1985;27:340–342.
Lodise TP, Rhoney DH, Tam VH, McKinnon PS, Drusano GL. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006;54(3):223–230.
Rhoney DH, Tam VH, Parker D, McKinnon PS, Coplin WM. Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003;23(3):310–314.
BrCAST. Brazilian Committee on Antimicrobial Susceptibility Testing – BrCAST. 2023. [cited 2023 Jul 16].